Navigation Links
Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Date:5/17/2009

Positive data from subgroup analysis presented at 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Helsinki, Finland

SAN DIEGO, May 17 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the results from its North American Phase 3 clinical study of fidaxomicin in patients with Clostridium difficile infection (CDI) were presented today by clinical investigator Thomas J. Louie, M.D. for the first time in an oral presentation at the 19th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Helsinki, Finland.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Dr. Louie presented the positive top-line results that the Company had previously announced in November 2008. The trial met its primary endpoint with fidaxomicin achieving clinical cure compared to Vancocin(R). In addition, patients treated with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure (cure with no recurrence within four weeks) compared to Vancocin (p=0.006).

"This study showed that fidaxomicin is as effective as vancomycin for treatment of C. Difficile diarrhea, including treatment of infection by the hyper virulent NAP1/ribotype 027 outbreak strain. Moreover, compared to vancomycin, recurrence of CDI is significantly less likely to occur following fidaxomicin therapy. Combining cure of CDI and freedom from recurrence, fidaxomicin is superior to vancomycin as treatment for this serious and common cause of infectious diarrhea," said Thomas J. Louie, M.D., Medical Director, Infection Prevention and Control for the Calgary Health R
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
(Date:8/19/2014)... , Aug. 19, 2014 According to Kalorama ... needed to make Big Data in healthcare a reality, ... As part of the American Recovery and Reinvestment Act, ... record (EMR) projects and penalties will start applying soon ... Information, in its complete study of the EMR industry, ...
(Date:8/19/2014)... Aug. 19, 2014  Cardiva Medical, Inc. announced today ... a $16.5 million Series 3 private equity financing and ... The Company will use the proceeds of the Series ... commercial efforts for its VASCADE® Vascular Closure System in ... Investing in Series 3 private equity financing was ...
Breaking Medicine Technology:Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
(Date:8/20/2014)... (PRWEB) August 20, 2014 BuyCheapTicketsToEvents.com ... a wide selection of tickets to many events. Cheap NHL ... will begin in September. , Hockey fans are enthusiastic about ... obtain tickets for games. Now is the time to acquire ... begin in mere months. There will be a great deal ...
(Date:8/20/2014)... people grow older, they often have difficulty falling asleep ... in the morning. In individuals with Alzheimer,s disease, this ... especially pronounced, often leading to nighttime confusion and wandering. ... Israel Deaconess Medical Center (BIDMC) and the University of ... more fragmented with age. Reported online today in the ...
(Date:8/20/2014)... Mixberry Media announced today its new ... create a new source of revenue. , The innovative ... to a narration of their favorite news and articles ... Users can now multitask: read/write email, drink coffee, ... content. , Mixberry Media’s service converts news ...
(Date:8/20/2014)... August 20, 2014 Riverside Health System ... , who joined its Warsaw Medical Arts team earlier ... in Family Medicine, is accepting new patients. , Dameron, ... Medicine, completed his residency at the Mountain Area Health ... Virginia. , “I really like the rural aspect of ...
(Date:8/19/2014)... 20, 2014 As moms and dads prepare ... to return to the normal routine of dropping their little ... Kristen Yarker, MSc, RD encourages them to use the ... snack time. , Yarker explains, “Kids have small tummies, ... of giving them junk food handouts, use snack time as ...
Breaking Medicine News(10 mins):Health News:2014 NHL Preseason Tickets Are Among Top Selling Seats at Trusted Provider BuyCheapTicketsToEvents.com 2Health News:Research helps explain why elderly have trouble sleeping 2Health News:Research helps explain why elderly have trouble sleeping 3Health News:Mixberry Media, First To Offer Article Voice Narration with Integrated Audio Advertising 2Health News:Riverside Warsaw Medical Arts’ Dr. William Dameron Accepting New Patients 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 2Health News:Child Nutritionist Kristen Yarker Wants Parents to Rethink Kids’ Snacks This Fall 3
... FirmsPHILADELPHIA, Jan. 15 /PRNewswire/ -- Michael ... Centocor, Inc., an operating company of Johnson & ... public relations consultancy, Pitch360 Incorporated ( www.pitch360inc.com ). ... issues management consultancy that leverages its vast pharmaceutical ...
... aging causes broken bones to heal slowly, or not at ... Journal of Bone and Mineral Research . The research team ... of treatments designed to "rescue" healing capability lost to aging. ... healing keeps the two sides of a fractured bone from ...
... Enterprises Ltd. ("Beeston") (OTC-BB:BESE) a resource base company ... mineral properties, announced that its Board of Directors ... of its full media campaign. MicroCap Management has ... a launch pad for Beeston,s present and future ...
... Area Treatments Twice as Fast and Improves Patient Treatment ... SLTM ) today announced the launch of ... system for faster, more comfortable body shaping, contouring and ... of traditional Thermage tips, Body Tip 16.0 cuts body ...
... WINSTON-SALEM, N.C., Jan. 15 For consumers, the Internet,offers ... vacations; however,when it comes to finding the best doctor, ... days, there are Web sites that offer ratings on,everyone ... picking,the best restaurants and hotels in town are getting ...
... Outlines Steps Taken to Reduce Expenses in Light ... Mass., Jan. 15 Cynosure, Inc. (NASDAQ: ... of a broad array of light-based aesthetic treatment ... fourth quarter ended December 31, 2008.Cynosure expects to ...
Cached Medicine News:Health News:Former Johnson & Johnson Executive Gives Big Voice to Small Companies 2Health News:Researchers detail how aging undermines bone healing 2Health News:Researchers detail how aging undermines bone healing 3Health News:Researchers detail how aging undermines bone healing 4Health News:Beeston Retains MicroCap Management, LLC as Its Lead Corporate Communications and Broker Relations Firm 2Health News:Beeston Retains MicroCap Management, LLC as Its Lead Corporate Communications and Broker Relations Firm 3Health News:Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments 2Health News:Video: Solta Medical Introduces Advanced Thermage Body Tip 16.0 for Faster Body Shaping and Contouring Treatments 3Health News:DrScore.com Says: Know Your Source When Going Online To Review Your Doctor's Rating 2Health News:DrScore.com Says: Know Your Source When Going Online To Review Your Doctor's Rating 3Health News:Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008 2Health News:Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008 3Health News:Cynosure Provides Preliminary Financial Results for the Fourth Quarter of 2008 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: